Gene · 2348
FOLR1: folate receptor alpha
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FOLR1: folate receptor alpha. Genes, record 2348. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2348
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P15328 | Folate receptor alpha | 257 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents538
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026169921 A1 | 2026-08-13 | 37 | P15328 | Espacenet |
| EP 4772183 A2 | 2026-07-08 | 1 | P15328 | Espacenet |
| EP 4741423 A2 | 2026-05-13 | 12 | P15328 | Espacenet |
| US 12600781 B2 | 2026-04-14 | 139 | P15328 | Espacenet |
| EP 4684803 A1 | 2026-01-28 | 12 | P15328 | Espacenet |
| JP 2026004432 A | 2026-01-14 | 49 | P15328 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46491 | P15328 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46492 | P15328 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46493 | P15328 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46494 | P15328 | Espacenet |
1 to 10 of 538
See all 538 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| FARLETUZUMAB | CHEMBL1743016 | Folate receptor alpha inhibitor | INHIBITOR | ChEMBL |
| MIRVETUXIMAB | CHEMBL3545192 | Folate receptor alpha binding agent | BINDING AGENT | ChEMBL |
| MIRVETUXIMAB SORAVTANSINE | CHEMBL3545132 | Folate receptor alpha binding agent | BINDING AGENT | ChEMBL |
| VINTAFOLIDE | CHEMBL3039521 | Folate receptor alpha binding agent | BINDING AGENT | ChEMBL |
Trials46
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07218809 | MIRVETUXIMAB SORAVTANSINE | PHASE3 | ClinicalTrials.gov | |
| NCT07059845 | MIRVETUXIMAB SORAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT06890338 | MIRVETUXIMAB SORAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT06682988 | MIRVETUXIMAB SORAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT06390995 | MIRVETUXIMAB SORAVTANSINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05887609 | MIRVETUXIMAB SORAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT05622890 | MIRVETUXIMAB SORAVTANSINE | PHASE3 | ClinicalTrials.gov | |
| NCT05604209 | FARLETUZUMAB | PHASE1 | 2025-08-24 | ClinicalTrials.gov |
| NCT05483933 | MIRVETUXIMAB SORAVTANSINE | PHASE1 | 2025-12-23 | ClinicalTrials.gov |
| NCT05456685 | MIRVETUXIMAB SORAVTANSINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 46
See all 46 trialsNIH grants1,396
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FOLR1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 37 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 16 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 15 | 2025 |
| T32CA009531 | Training Program in the Biology of Cancer | 13 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 11 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 8 | 2025 |
| P30CA016359 | Cancer Center Support Grant | 7 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 7 | 2025 |
| P01CA254859 | Intraoperative Near Infrared Molecular Imaging of Lung Cancer | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 6 | 2025 |
1 to 10 of 1,396Source NIH's project files
See all 1,396 nih grantsPapers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Label-free fiber-optic cascade sensor for rapid and ultrasensitive serum folate quantification. | Talanta | 2027 | 42691716 | PubTator, text mining | PubMed |
| DOTAM-TCB: Universal Small Molecule-guided Hapten- and T Cell-bispecific Antibodies for Cancer Immunotherapy. | Antib Ther | 2026 | 42824820 | PubTator, text mining | PubMed |
| Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD? | Int J Womens Health | 2026 | 42824309 | PubTator, text mining | PubMed |
| An integrated microfluidic platform for tunable-stringency competitive affinity selection of folate receptor alpha aptamers. | Lab Chip | 2026 | 42820463 | PubTator, text mining | PubMed |
| Plasma and cerebrospinal fluid proteomics reveal distinct patterns of senescence and neuropathology in aging rhesus macaques. | Geroscience | 2026 | 42799938 | PubTator, text mining | PubMed |
| Prenatal Folinic Acid in FRAA-Positive Pregnancies: Preschool Neurodevelopmental Outcomes from a Pilot RCT Follow-Up. | Nutrients | 2026 | 42796952 | PubTator, text mining | PubMed |
| Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia. | Haematologica | 2026 | 42779343 | PubTator, text mining | PubMed |
| Near-Infrared Fluorescent Zwitterionic Folic Acid Probe and Serum CA125 for Enhancing Diagnostic Accuracy of Malignant Ovarian Cancer Ascites. | Technol Cancer Res Treat | 2026 | 42753264 | PubTator, text mining | PubMed |
| Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System. | J Gynecol Oncol | 2026 | 42750304 | PubTator, text mining | PubMed |
| Comparative Transcriptomic and Immune Profiling Reveals a Shared Molecular Identity Between Clear Cell Odontogenic Carcinoma and Hyalinizing Clear Cell Carcinoma. | Mol Cancer Res | 2026 | 42743086 | PubTator, text mining | PubMed |
1 to 10 of 3,253
See all 3,253 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2348
GET https://conductscience.org/api/genes/v1/2348/patents?page=2